National and Kapodistrian University of Athens
Ανοσοϊστοχημική μελέτη της ογκογόνου πρωτεΐνης Υ-box binding protein-1 (Yb-1) σε διηθητικά καρκινώμτα μαστού
Abstract
dc:descriptionYB-1 protein is a transcriptional - translational factor, belongs to the family of proteins that bind DNA and RNA and contains a well-conserved cold shock domain which interacts with inverted CCAAT-boxes (Y-boxes) found in the promoters of various eukaryotic genes and particularly genes related to cell growth and proliferation. YB-1 is found predominantly in the cytoplasm of cells and a small proportion can be found in the nucleus at the G1 / S phase of the cell cycle as a response to extracellular stimuli such as hyperthermia, UV irradiation and after treatment with thrombin, interferon and insulin-like growth factor 1 (IGF-1). YB - 1 is overexpressed in a variety of carcinomas (e.g. prostate, colon, ovarian, lung and bone (multiple myeloma) carcinomas, in glioblastoma) as well as in breast cancer.The purpose of this study was to investigate the expression pattern of YB - 1 protein in 225 invasive breast carcinomas. The results of this marker were statistically analyzed in order to investigate their correlation with: a) Classic clinicopathologic parameters (age, menopausal status, tumor size, histological type, histological and nuclear grade, lymph node status, stage of disease), b) Modern prognostic markers, such as the immunohistochemical expression of hormone receptors ER, PR and the oncoprotein HER-2, c) signaling molecules, such as the immunohistochemical expression of Ki-67, p53, bcl-2 proteins, d) the phenotype CD44+/CD24-/low , which is considered to represent breast cancer stem cells and e) total and disease-free patients’ survival. Based on the correlations obtained, an estimation of the possible involvement of protein YB -1 in aggressiveness and prognosis of breast cancer is made.The material consisted of 225 primary invasive breast carcinomas of which 169 were ductal and 50 lobular, derived from 225 female patients aged 25-87 years. The median follow-up for overall survival was 189 months. Sixty-five patients were presented with relapse, with a median follow-up period of 189 months. For the determination of the protein, the three step immunohistochemical method of the avidin - biotin – peroxidase complex was applied. Statistical analysis of the results and the individual correlations was performed by univariate (chi-square test and log rank test) and multivariate (Cox's hazard regression model) analysis. Results: YB-1 protein was detected in the cytoplasm and nucleus of cancer cells in 93 (41.3%) and 52 (23.10%) cases, respectively, and in stromal fibroblasts in 123 (55%) cases. The cytoplasmic expression of the protein was associated with the premenopausal state of the patients (p=0,018), with invasive ductal carcinomas (p = 0,002), positively with nuclear grade (p<0,001), inversely with the expression of ER and Bcl -2 proteins (p=0,002 and p=0,042, respectively), positively with the expression of the proteins Ki-67 and p53 (p=0,022 and p=0,002, respectively) and positively with the phenotype CD44+/CD24-/low (p=0,001). The localization of the protein in this cellular compartment was not found to exert influence on overall and disease - free patients’ survival. Nuclear expression of YB-1, while not associated with any of the prognostic markers of breast cancer or any of the novel biomarkers, was found to exert an unfavorable impact on disease - free survival: a) of all patients (p=0,05), b) of patients who received adjuvant radiotherapy or chemotherapy (p=0,036 and p=0,05, respectively), c) of patients with lobular carcinomas (p=0,006), d) of patients with carcinomas which simultaneously lacked ER and PR receptors (p=0,008), e) of patients with carcinomas positive for the expression of the receptor HER-2 (p=0,018) and f) of patients with carcinomas of the HER-2 molecular subtype [ER(-)/PR(-)/HER-2(+)] (p=0,023). The stromal expression of YB -1 was not correlated with any of the clinicopathologic parameters of breast cancer or patients’ survival. However, it was found to be positively associated with the expression of HER-2 and p53 proteins (p=0,011 and p=0,021, respectively) and inversely with the expression of the protein Bcl-2 (p=0,018). In conclusion, the results of the protein suggest that the cytoplasmic localization of YB-1 is associated with a more aggressive phenotype of breast cancer. The nuclear localization of YB-1 was correlated with a worse disease-free survival in all patients. Further, the negative correlation between nuclear YB-1 and disease-free survival of the patients who received adjuvant radiotherapy or chemotherapy, highlights the importance of the protein in the acquisition of resistance in various therapeutic regimens used for the treatment of breast cancer and thus could be considered as a possible prognostic and predictive marker.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2014
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Melissaris, Savvas
- Μελισσάρης, Σάββας
Subjects
dc:subject × 16- Πρωτεΐνη Yb-1
- Καρκίνωμα μαστού
- Ανοσοϊστοχημεία
- Αρχέγονα καρκινικά κύτταρα
- Πρωτείνη CD44+/CD24 - low
- Ptotein Yb-1
- Breast cancer
- Immunohistochemistry
- Cancer stem - stells
- Ptotein CD44+/CD24 - low
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Άλλες Ιατρικές Επιστήμες
- Medical and Health Sciences
- Clinical Medicine
- Other Medical Sciences
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/40824